Virax Biolabs Group Limited

About Virax Biolabs Group Limited

Virax Biolabs is a company focused on innovation in immunology, dedicated to developing immune profiling solutions and T cell diagnostics. Their mission is to accelerate the path to more effective vaccines and create lasting, impactful change in global health through research tools and diagnostic technologies.

Products & Services

ViraxImmune™:A platform for novel PAIS diagnostic development and immune profiling, not restricted to a single disease or condition.

Peptide Pools:Pathogen-specific linear peptides containing immunodominant epitopes, designed for efficient T cell stimulation.

ELISpot/FluoroSpot Kits:Pre-coated plates and reagents to analyze immune responses at the cellular level, with multiple cytokines available.

Antibodies:High-affinity antibodies for the detection of cytokines and other biomarkers in ELISA, Flow Cytometry, and ELISpot assays.

Specialties

Immunology T Cell Diagnostics Immune Profiling Vaccine Efficacy Testing Diagnosis of Viral Diseases Chronic Inflammation Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2025-12-04 FD: 2025-12-04	-
2	RT: Private Placement T: - FT: Private Placement	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2025-12-03 FD: 2025-12-03	-
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 5000000 MR: - FA: 5 million FAN: 5000000	D: 2024-08-23 FD: 2024-08-23	1 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2024-08-21 FD: 2024-08-21	-
5	RT: Private Placement T: - FT: Private Placement	A: 4000000 MR: - FA: approximately $4 million FAN: 4000000	D: 2023-03-10 FD: 2023-03-10	-
6	RT: Private Placement T: - FT: Private Placement	A: 4000000 MR: - FA: 4 million FAN: 4000000	D: 2023-03-08 FD: 2023-03-08	-

Private Placement Latest

2025-12-04

$5.0M

Private Placement 2025-12-03

$5.0M

Registered Direct Offering 2024-08-23

$5.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

James Foster

Chief Executive Officer

D

Dr. Nigel McCracken

Chief Operating Officer

D

Dr. Clement Monteil

Head of R&D

D

Dr. Iain Miller

Independent Director

E

Evan Norton

Independent Director

N

Nelson Haight

Independent Director

View 8 more team members with Pro

Unlock Full Team Directory

Recent News